Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric carboxymaltose - Vifor

Next Previous
Drug Profile

Ferric carboxymaltose - Vifor

Alternative Names: Ferinject; Injectafer; Iron-dextri-maltose; Iroprem; Renegy; VIT-45; Z-213

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vifor
  • Developer American Regent; Duke Clinical Research Institute; JW Pharmaceutical; Vifor; Zeria
  • Class Antianaemics; Cardiovascular therapies; Heavy metals; Iron compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Restless legs syndrome

Most Recent Events

  • 29 Mar 2024 Vifor Pharma announces intention to launch ferric carboxymaltose for Iron deficiency anaemia in Canada in the second half of 2024
  • 19 Mar 2024 Registered for Iron deficiency anaemia (In infants, In children, In adolescents, In adults, Treatment-experienced) in Canada (IV)
  • 28 Aug 2023 Efficacy data from the phase III HEART-FID trial in Iron deficiency released by American Regent
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top